RU2020122545A3 - - Google Patents

Download PDF

Info

Publication number
RU2020122545A3
RU2020122545A3 RU2020122545A RU2020122545A RU2020122545A3 RU 2020122545 A3 RU2020122545 A3 RU 2020122545A3 RU 2020122545 A RU2020122545 A RU 2020122545A RU 2020122545 A RU2020122545 A RU 2020122545A RU 2020122545 A3 RU2020122545 A3 RU 2020122545A3
Authority
RU
Russia
Application number
RU2020122545A
Other languages
Russian (ru)
Other versions
RU2790233C2 (ru
RU2020122545A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020122545A publication Critical patent/RU2020122545A/ru
Publication of RU2020122545A3 publication Critical patent/RU2020122545A3/ru
Application granted granted Critical
Publication of RU2790233C2 publication Critical patent/RU2790233C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2020122545A 2017-12-15 2018-12-07 Иммуностимулирующие олигонуклеотиды RU2790233C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17207750 2017-12-15
EP17207740 2017-12-15
EP17207750.5 2017-12-15
EP17207746 2017-12-15
EP17207740.6 2017-12-15
EP17207746.3 2017-12-15
PCT/EP2018/084019 WO2019115402A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Publications (3)

Publication Number Publication Date
RU2020122545A RU2020122545A (ru) 2022-01-19
RU2020122545A3 true RU2020122545A3 (enExample) 2022-05-04
RU2790233C2 RU2790233C2 (ru) 2023-02-15

Family

ID=

Also Published As

Publication number Publication date
PE20200933A1 (es) 2020-09-17
SG11202004773SA (en) 2020-06-29
US11932857B2 (en) 2024-03-19
WO2019115386A9 (en) 2020-07-23
CA3085575A1 (en) 2019-06-20
ZA202004317B (en) 2023-05-31
US20250215439A1 (en) 2025-07-03
EP3701032A1 (en) 2020-09-02
DOP2020000113A (es) 2020-08-31
TWI821224B (zh) 2023-11-11
ES3052969T3 (en) 2026-01-16
JP7273040B2 (ja) 2023-05-12
JP7760560B2 (ja) 2025-10-27
WO2019115386A1 (en) 2019-06-20
AU2018385257A1 (en) 2020-06-18
MX2020006246A (es) 2020-09-03
MX2025007909A (es) 2025-08-01
TWI911138B (zh) 2026-01-11
TW201936923A (zh) 2019-09-16
IL275217A (en) 2020-07-30
JP2023153970A (ja) 2023-10-18
CO2020007102A2 (es) 2020-06-19
BR112020011845A2 (pt) 2020-11-24
CN111801116A (zh) 2020-10-20
CA3085657A1 (en) 2019-06-20
PH12020550906A1 (en) 2021-05-17
KR102787688B1 (ko) 2025-03-27
AU2018385256B2 (en) 2025-09-25
EP4647437A2 (en) 2025-11-12
TW201936924A (zh) 2019-09-16
KR20200098638A (ko) 2020-08-20
CN111447949A (zh) 2020-07-24
RU2020122553A (ru) 2022-01-17
DOP2020000107A (es) 2020-08-31
CR20200260A (es) 2020-08-01
CN111447949B (zh) 2025-07-11
CN119656298A (zh) 2025-03-21
UY38014A (es) 2019-06-28
CL2020001562A1 (es) 2020-11-06
BR112020011838A2 (pt) 2020-11-24
DK3700564T3 (da) 2025-11-10
TWI900461B (zh) 2025-10-11
RU2020122545A (ru) 2022-01-19
PH12020550903A1 (en) 2021-05-17
CL2020001560A1 (es) 2020-11-06
KR20250048594A (ko) 2025-04-09
US20210062192A1 (en) 2021-03-04
PE20210636A1 (es) 2021-03-23
UY38016A (es) 2019-06-28
EP3700564B1 (en) 2025-09-17
BR112020011815A2 (pt) 2020-11-17
JP7770769B2 (ja) 2025-11-17
AU2018385256A1 (en) 2020-06-11
AU2018382419B2 (en) 2025-04-10
AU2025205082A1 (en) 2025-07-31
EP3700564A1 (en) 2020-09-02
CL2020001561A1 (es) 2020-11-06
KR20200099556A (ko) 2020-08-24
US20230332162A1 (en) 2023-10-19
KR20200098637A (ko) 2020-08-20
MX2020006244A (es) 2020-09-03
US20210170020A1 (en) 2021-06-10
PL3700564T3 (pl) 2026-02-23
JP2021506779A (ja) 2021-02-22
WO2019115385A1 (en) 2019-06-20
CN120519464A (zh) 2025-08-22
PH12020550904A1 (en) 2021-05-17
JP2023156485A (ja) 2023-10-24
US11542507B2 (en) 2023-01-03
CN111801116B (zh) 2024-11-26
IL274975A (en) 2020-07-30
US20200385733A1 (en) 2020-12-10
PE20210635A1 (es) 2021-03-23
AU2025204678A1 (en) 2025-07-17
AU2018382419A1 (en) 2020-06-04
UY38015A (es) 2019-06-28
US20230174990A1 (en) 2023-06-08
SG11202004952UA (en) 2020-06-29
US12305173B2 (en) 2025-05-20
JP7458977B2 (ja) 2024-04-01
EP4647437A3 (en) 2026-02-18
WO2019115402A1 (en) 2019-06-20
MX2020006243A (es) 2020-09-03
SG11202004471RA (en) 2020-06-29
CO2020007120A2 (es) 2020-06-19
US20240076681A1 (en) 2024-03-07
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
EP3694549A1 (en) 2020-08-19
CA3085661A1 (en) 2019-06-20
DOP2020000106A (es) 2020-08-31
JP2021506246A (ja) 2021-02-22
AU2018385257B2 (en) 2025-04-10
IL275086A (en) 2020-07-30
JP2021506245A (ja) 2021-02-22
TW201940192A (zh) 2019-10-16

Similar Documents

Publication Publication Date Title
BR122021000189A2 (enExample)
BR112019008823A2 (enExample)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020006283B1 (pt) Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico
BR112020009729B1 (pt) Inibidores de acss2 e métodos de uso dos mesmos
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112020001262B1 (pt) Processo para preparar uma composição de entrega de fármaco
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR102018003507B1 (pt) Sistema de isolamento de tensão de tambor de guincho
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019014127B1 (pt) Composição farmacêutica para tratamento de tumores
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR102017026429B1 (pt) Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros
BR112020006250B1 (pt) Primeira estação base e método de controle de estado em uma primeira estação base
BR112020009084B1 (pt) Método de operação de um nó de rádio alvo, nó de rádio alvo, método de operação de um nó de rádio de transmissão, nó de rádio de transmissão, e, meio de armazenamento não transitório legível por computador
BR112020008456B1 (pt) Terminal e método de transmissão para um terminal